2,3,5-Substituted Thiophene Combinations for Bcl-2 Leukemia Therapy
Solution Overview
Problem
Current anticancer drugs for leukemia, such as cisplatin, cause significant adverse effects and exhibit efficacy only in a small group of patients, necessitating the development of precision medicine for personalized treatment.
Innovation Solution
A pharmaceutical composition comprising a 2,3,5-substituted thiophene compound, represented by Formula 1, in combination with anticancer drugs like bc12 inhibitors (cytarabine, venetoclax, or azacitidine), for the prevention or treatment of leukemia, utilizing a companion diagnosis to select effective patient groups.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anticancer drugs (cisplatin, mitomycin-C, adriamycin) are used to treat leukemia, then cancer treatment efficacy is improved, but adverse effects (hematopoietic toxicity, gastrointestinal toxicity, kidney toxicity, hearing loss, peripheral nerve abnormalities) increase significantly
Solution Approach 1:
The patent segments the treatment approach by using a combination of two distinct compounds (2,3,5-substituted thiophene compound and bc12 inhibitor) rather than a single conventional drug. This segmentation allows each compound to contribute differently to the therapeutic effect, potentially reducing the burden of adverse effects while maintaining or improving efficacy.
Solution Approach 2:
The patent employs a composite therapeutic approach by combining a 2,3,5-substituted thiophene compound with a bc12 inhibitor. This composite formulation leverages the synergistic effects of both compounds to achieve superior anti-leukemia activity while potentially reducing the toxicities associated with conventional single-agent therapies.
2Reliability
If conventional anticancer drugs are used for leukemia treatment, then some patients respond to treatment, but efficacy is limited to only a small group of patients, requiring precision medicine approaches
Solution Approach 1:
The patent utilizes companion diagnosis to identify specific patient populations (those with Bcl-2 expressing leukemia cells) who are most likely to respond to the combination therapy. By changing the selection parameter from general leukemia diagnosis to specific molecular characterization, the treatment becomes more effective for the target population.
Solution Approach 2:
The patent introduces companion diagnosis as an intermediary step between leukemia diagnosis and treatment selection. This intermediary process identifies patients with specific Bcl-2 expression patterns, enabling precise matching of the combination therapy to the appropriate patient population and improving overall treatment efficacy.
3Ease of operation
If single-agent chemotherapy is used for leukemia, then treatment simplicity is maintained, but inhibitory activity against leukemia cells is insufficient compared to combination therapy
Solution Approach 1:
The patent merges two therapeutic agents (2,3,5-substituted thiophene compound and bc12 inhibitor) into a single combination therapy regimen. This merging approach enhances inhibitory activity against leukemia cells through synergistic effects while maintaining relative treatment simplicity through coordinated administration of the two compounds.
Data Source
AI summary
The present invention relates to a composition for co-administration containing a 2,3,5-substituted thiophene compound. The composition has excellent inhibitory activity against cancer cells related to leukemia compared to treatment with the 2,3,5-substituted thiophene compound alone or an anticancer drug alone, and thus may be useful for the prevention, amelioration or treatment of leukemia.